Anti-gonadotrophin releasing hormone vaccine - Aphton/GlaxoSmithKline

Drug Profile

Anti-gonadotrophin releasing hormone vaccine - Aphton/GlaxoSmithKline

Alternative Names: GnRH immunogen; GnRH pharmaccine; Gonadimmune™

Latest Information Update: 07 Dec 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Aphton Corporation
  • Developer Aphton Corporation; GlaxoSmithKline
  • Class Antiandrogens; Antiprogestogens; Vaccines
  • Mechanism of Action Estrogen receptor antagonists; Gonadotropin releasing hormone inhibitors; Immunostimulants; Progesterone receptor antagonists; Testosterone antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Endometrial cancer; Endometriosis; Prostate cancer

Most Recent Events

  • 07 Jun 2006 Discontinued - Phase-II for Prostate cancer in Europe (IM)
  • 07 Jun 2006 Discontinued - Phase-II for Prostate cancer in USA (IM)
  • 07 Jun 2006 Discontinued - Preclinical for Breast cancer in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top